Interestingly, whereas the KRAS mutationdetection rate in localized and metastatic pancreatic cancer was nearly equivalent for thecfDNA and EV DNA analyses, surgically resected primary tissue samples showed 95.5%concordance with the EV DNA-based assessment and only 68.2% concordance with the cfDNAanalysis results. This evidence concerns the gene KRAS and familial pancreatic carcinoma.